Ultima Genomics
Ultima Genomics develops high-throughput, low-cost DNA sequencing instruments (UG 100 and UG200 Series) based on a silicon-wafer substrate and paired plus-minus (ppmSeq) chemistry, serving research institutions, clinical labs, population-genomics consortia, and consumer-genomics service providers via direct sales and a global Certified Service Provider network.
- Company typePrivate
- Founded2016
- HeadquartersNewark, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Ultima Genomics does
Ultima Genomics is a venture-backed developer of high-throughput, low-cost DNA sequencing instruments and consumables, founded in 2016 by Gilad Almogy (formerly of Applied Materials) and headquartered in the San Francisco Bay Area. The company emerged from stealth in May 2022 alongside a $600M financing round and has subsequently raised cumulative capital exceeding $700M from a tier-1 investor syndicate led by Andreessen Horowitz and including Khosla Ventures, General Atlantic, Lightspeed, Playground Global, D1 Capital, Founders Fund, and aMoon. Its installed base spans research institutions, clinical laboratories, consumer genomics services, and pharmaceutical R&D programs across North America, EMEA, and APAC, with distribution supported by a global Certified Service Provider network of 12+ providers including Broad Clinical Labs, IQVIA Laboratories, Macrogen, Novogene, and Gene By Gene.
The company's core technology is a sequencing-by-synthesis architecture built on an open 200mm silicon wafer substrate (replacing conventional glass flow cells) with flow-based chemistry and rotational imaging. Its product family comprises the UG 100 and the 2026-launched UG200 Series (single-wafer UG200 and dual-wafer UG200 Ultra), paired with Solaris / Solaris 2.0 amplification and library-prep chemistry and the proprietary ppmSeq (paired plus-minus sequencing) error-correction method that achieves part-per-million SNV accuracy by sequencing both strands of each template. List pricing for UG 200-series instruments is reported at $850K–$1.25M, with per-genome consumable pricing as low as $80 at 30x coverage and throughput capacity exceeding 60,000 whole genomes per year on a single UG 200 Ultra. The integrated software stack includes on-board secondary analysis plus UG-adapted DeepVariant, Sentieon DNAscope, and GATK pipelines, with open-source WDL workflows available on AWS HealthOmics.
Revenue is generated through three streams: capital sales of sequencing instruments, recurring consumables (single-use wafers, reagents, adapters, and Solaris library-prep kits), and sequencing-as-a-service via the in-house Technology Access Program. The model is hybrid — direct enterprise sales for instruments and TAP, complemented by the CSP channel that delivers Ultima sequencing capacity to end customers without instrument purchase. Focus application areas include population-scale germline whole-genome sequencing, oncology and minimal-residual-disease detection, single-cell and spatial transcriptomics, proteomics, and methylation profiling, with a large integration ecosystem spanning 10x Genomics, Olink, Parse Biosciences, BD, Scale Bio, BioSkryb, IDT, Twist, NEB, Watchmaker, Fabric Genomics, NVIDIA, AWS, Sentieon, GATK, Sapio Sciences, and Hamilton.
Ultima Genomics firmographics
Firmographics- Name
- Ultima Genomics
- Legal name
- Ultima Genomics, Inc.
- Website
- https://ultimagenomics.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Ultima Genomics develops high-throughput, low-cost DNA sequencing instruments (UG 100 and UG200 Series) based on a silicon-wafer substrate and paired plus-minus (ppmSeq) chemistry, serving research institutions, clinical labs, population-genomics consortia, and consumer-genomics service providers via direct sales and a global Certified Service Provider network.
- Ownership category
- akta.pro rank
Ultima Genomics industry classification
Industry- Product category
- DNA Sequencing Instruments
- NAICS
- Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Laboratory Analytical Instruments (3826), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)
Keywords
Where Ultima Genomics is headquartered
LocationHeadquarters
- HQ city
- Newark
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Ultima Genomics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Instrument hardware sales: One-time capital sales of UG 100, UG 200, and UG 200 Ultra sequencing systems to research and clinical laboratories (priced from ~$850,000 to ~$1,250,000 per instrument).
- Consumables (wafers, reagents, adapters, library prep kits): Recurring revenue from single-use wafer consumables, flow reagents, sequencing adapters, and Solaris / Solaris 2.0 library preparation kits that attach to the installed instrument base.
- Technology Access Program (sequencing services): Fee-for-service sequencing operated by Ultima Genomics itself; customers submit samples and receive data, providing an alternative path to access without instrument purchase.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Usage-based | Pay-as-you-go | UG 100 sequencing consumables with Solaris prep at $80 per 30x human genome |
| One time/ perpetual license | Multi-year contract | UG 200 Ultra sequencer list price $1,250,000 |
| One time/ perpetual license | Multi-year contract | UG 200 / UG 200 Ultra list prices starting as low as $850,000 |
| Other | Pay-as-you-go | Technology Access Program (TAP) sequencing services |
Go-to-market motion4 records
Distribution channels4 records
Marketing channels8 records
Ultima Genomics product offering
Product offeringCore offering
Ultima Genomics develops and sells high-throughput DNA sequencing instruments (UG 100, UG200, UG200 Ultra) built on a proprietary open 200mm silicon wafer substrate and flow-based sequencing-by-synthesis chemistry, paired with recurring consumables (wafers, reagents, Solaris/Solaris 2.0 library prep, ppmSeq paired plus-minus chemistry) and on-board analysis software. The company also operates a Technology Access Program providing sequencing-as-a-service and a global Certified Service Provider network for sample-to-data delivery.
Differentiator
Problem solved
Functional benefit
Brands
- UG 100 Sequencing Platform: High-throughput, low-cost sequencing platform featuring an open 200mm silicon wafer substrate and mostly natural sequencing-by-synthesis flow chemistry.
- UG200 Series
- ppmSeq
- Solaris 2.0
Products and services
- UG 100 Sequencing Platform First-generation high-throughput DNA sequencing instrument built on an open 200mm silicon wafer substrate with rotational imaging and mostly natural flow-based sequencing-by-synthesis chemistry. With Solaris workflows the platform delivers 10-12 billion reads per wafer at $0.24 per million reads, supporting up to 30,000+ whole genomes per year for research and clinical laboratories.
- UG200 Series (UG200 and UG200 Ultra) Second-generation sequencing instrument platform launched in February 2026 with two configurations (UG200 single-wafer and UG200 Ultra dual-wafer) delivering doubled output, halved runtime, and halved footprint versus the UG 100. Uses rapid isothermal amplification for seamless lab automation integration; UG200 Ultra sequences more than 60,000 whole genomes per year at 30x coverage and runs up to 60 automated runs per week with single-shift operation.
- ppmSeq (paired plus-minus sequencing) Paired plus-minus sequencing chemistry that achieves one part-per-million or better SNV detection accuracy by sequencing both strands of a captured DNA molecule and removing disagreement caused by sample errors. Enables part-per-million rare variant detection in liquid biopsy and minimal residual disease (MRD) applications and supports 30x whole-genome sequencing from 2ng of cfDNA.
- Solaris Free and Solaris Flex library prep workflows Library preparation workflows for the UG 100 sequencing platform. Solaris Free provides PCR-free library prep compatible with leading third-party library prep kits (e.g., xGen PCR-Free Adapters for Ultima Genomics from IDT and UG ppmSeq Adapters), while Solaris Flex adapts existing third-party libraries through a simple indexing PCR step.
- Solaris 2.0 amplification chemistry and library prep workflows Next-generation amplification chemistry and library prep workflows for the UG200 Series, featuring Solaris 2.0 Free (PCR-free) and Solaris 2.0 Flex (indexing PCR) workflows with improved GC coverage uniformity and variant calling accuracy. Solaris 2.0 Max provides up to 20 billion reads per wafer with a 7-hour amplification workflow requiring only 10 minutes of hands-on time.
- Analysis & Bioinformatics Solutions Integrated software suite with on-board UG 100 Server performing primary and secondary analysis without impacting sequencing throughput. Includes the Ultima Aligner optimized for flow chemistry, on-board demultiplexing, UMI-aware deduplication, alt-aware alignment, and compatibility with UG-adapted DeepVariant, Sentieon DNAscope, GATK UG flow mode, and AWS HealthOmics cloud workflows.
- Certified Service Provider (CSP) Network Global network of rigorously vetted service providers offering Ultima sequencing services to end customers. Includes Broad Clinical Labs, Gene By Gene, Inocras, IQVIA Laboratories, Macrogen, McGill Genome Centre, New York Genome Center, Novogene Americas, Ontario Institute for Cancer Research, Psomagen, University of Michigan Advanced Genomics Core, and University of Minnesota Genomics Center.
- Technology Access Program (TAP) In-house sequencing-as-a-service program that provides access to Ultima's applications lab and high-capacity fleet of UG 100 sequencers, including consultation, sample submission, sequencing, QC, bioinformatics analysis, and ongoing support from consultation through data interpretation.
Quantifiable outcome
- More than 60,000 30x whole genomes per year on a single UG 200 Ultra
- +3 more outcomes
Companies that use Ultima Genomics
Customer profileNamed customers18 records
Segments4 records
Ideal customer profiles4 records
Ultima Genomics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration19 records
AI capability6 records
Feature5 records
Ultima Genomics partnerships and signals
Strategic signalPartnerships
34 partnerships are on record, tiered flagship and core.
- Hartwig Medical FoundationflagshipStrategic collaboration on population-scale whole-genome oncology sequencing. Co-develops workflows around ppmSeq and the UG 200 platform to advance cancer genomics research.
- MacrogencoreCo-hosted AI genome analysis symposium to expand Ultima adoption across APAC. Macrogen also acts as a Certified Service Provider.
- Basecamp ResearchflagshipJoint Trillion Gene Atlas initiative covering 31 countries; Ultima provides sequencing capacity and ppmSeq accuracy while Basecamp contributes biodiversity and discovery data assets.
- Hamilton CompanycoreAutomation partnership integrating Hamilton liquid-handling robotics with Ultima's sequencing workflows to enable high-throughput laboratory automation.
- MyHeritageflagshipStrategic partnership to deliver a consumer whole-genome sequencing testing product powered by Ultima's technology.
- Gene By GeneflagshipWhole-genome sequencing service partnership; Gene By Gene operates 100,000-sample-per-month capacity using Ultima instruments and is also a Certified Service Provider.
- Sapio SciencescoreLab informatics partnership integrating Sapio's lab informatics platform with Ultima sequencing workflows to streamline sample-to-data pipelines.
- Chan Zuckerberg InitiativecorePartner on the Billion Cells Project leveraging Ultima sequencing for large-scale single-cell research.
- 10x GenomicsflagshipTechnology integration combining 10x single-cell and spatial transcriptomics with Ultima sequencing for large-scale single-cell studies.
- OlinkcoreProteomics integration combining Olink's proteomic assays with Ultima sequencing workflows.
- Parse BiosciencescoreSingle-cell integration combining Parse's single-cell chemistry with Ultima sequencing.
- Scale BiosciencescoreSingle-cell technology integration with Ultima sequencing.
- Integrated DNA Technologies (IDT)coreLibrary prep integration with IDT's reagents for use on Ultima sequencers.
- Twist BiosciencecoreLibrary prep integration using Twist's synthetic biology reagents on the Ultima platform.
- New England Biolabs (NEB)coreLibrary prep integration with NEB reagents for Ultima sequencing workflows.
- Watchmaker GenomicscoreLibrary prep integration with Watchmaker's enzymes for use on Ultima sequencers.
- Fabric GenomicscoreAnalysis integration providing tertiary / clinical interpretation for Ultima sequencing data.
- Amazon Web Services (AWS)flagshipCloud infrastructure integration enabling Ultima customers to run genomic analysis workflows on AWS.
- NVIDIAflagshipInfrastructure partnership leveraging NVIDIA accelerated computing for secondary analysis of Ultima sequencing data.
- SentieoncoreAnalysis integration using Sentieon's variant calling pipelines optimized for Ultima data.
- GATKcoreAnalysis integration with the Broad's GATK best-practices pipelines for Ultima sequencing data.
- Becton Dickinson (BD)coreSingle-cell technology integration combining BD's single-cell portfolio with Ultima sequencing.
- Broad Clinical LabscoreCertified Service Provider based in Boston, MA offering Ultima sequencing services to its clinical and research customers.
- Gene By GeneflagshipCertified Service Provider in Houston, TX operating the largest commercial deployment of Ultima sequencers with capacity for 100,000 whole genomes per month.
- InocrascoreCertified Service Provider in San Diego, CA offering Ultima-powered clinical genomics, including MRD and cancer applications.
- IQVIA LaboratoriesflagshipCertified Service Provider in Durham, NC leveraging Ultima sequencing for large-scale clinical and pharmaceutical genomics programs.
- MacrogenflagshipCertified Service Provider based in Seoul, South Korea offering Ultima sequencing capacity across APAC.
- McGill Genome CentrecoreCertified Service Provider based in Montreal, Canada offering Ultima sequencing to academic researchers.
- New York Genome CenterflagshipCertified Service Provider in New York, NY offering Ultima sequencing to the NYC research community.
- Novogene AmericasflagshipCertified Service Provider in Beaverton, OR offering Ultima sequencing across North America.
- Ontario Institute for Cancer ResearchcoreCertified Service Provider in Ontario, Canada using Ultima sequencing for oncology research programs.
- PsomagencoreCertified Service Provider in Rockville, MD offering Ultima sequencing to clinical and research customers.
- University of Michigan Advanced Genomics CorecoreCertified Service Provider running Ultima sequencing for University of Michigan researchers and external customers.
- University of Minnesota Genomics CentercoreCertified Service Provider offering Ultima sequencing to University of Minnesota researchers and external customers.
Scale indicators7 records
Recent moves7 records
Expansion highlights7 records
Ultima Genomics competitors and assessment
Company assessmentBroad incumbents
- Illumina: Dominant incumbent in short-read next-generation sequencing with an estimated majority share of installed sequencers worldwide. Ultima directly competes against Illumina's NovaSeq, NextSeq, and iSeq platforms on throughput and per-genome cost, while targeting Illumina's installed base through cost disruption.
- NeoGenomics: Clinical oncology laboratory services company with a large installed clinical footprint in oncology testing. NeoGenomics is a partnership customer for Ultima but also a competitor/alternative for clinical WGS and MRD testing in oncology, especially where labs default to incumbent platforms.
Direct peers
- Pacific Biosciences: Long-read sequencing platform (Revio, Sequel) competing for population-scale and clinical genomics workloads alongside Ultima. Pacific Biosciences shares much of Ultima's enterprise sales motion and several of Ultima's senior leaders (e.g., Chris Seipert, Lara Toerien, Jason Kang) come from PacBio, and they are co-collaborators on Basecamp Research's Trillion Gene Atlas.
- Oxford Nanopore Technologies: Nanopore-based long-read sequencing provider competing across research, clinical, and applied genomics markets. Both companies pursue population-scale sequencing economics and clinical oncology applications, and both compete for the same academic and translational research budgets.
- MGI Tech (BGI Group): Low-cost NGS and DNA nanoball sequencing platforms (DNBSEQ) positioned as the most direct cost-disruptive competitor to Ultima, particularly in APAC. MGI's aggressive pricing mirrors Ultima's per-genome economics, making it the primary head-to-head competitor for population-scale and clinical WGS contracts.
- Element Biosciences: Emerging NGS platform (AVITI) targeting low-cost, high-accuracy short-read sequencing with a novel avidity-based chemistry. Element is the closest US-based emerging competitor to Ultima on cost-per-sample and accuracy, competing for the same research and clinical early-adopter accounts.
- Complete Genomics: Sequencing instruments and services (now under MGI/BGI) historically positioned for low-cost human whole-genome sequencing. Comparable to Ultima in technology philosophy and population-scale WGS ambitions; BGI integration increases scale and competitive overlap.
Emerging players
- Singular Genomics: Developer of the G4 benchtop sequencing platform targeting multiomic applications including single-cell, spatial, and targeted sequencing. Singular competes with Ultima at the lower-throughput / mid-size lab end of the market rather than Ultima's population-scale footprint.
- GenapSys: Early-stage low-cost sequencing platform using electrical detection. Florian Oberstrass (SVP Technology Development at Ultima) previously led R&D at GenapSys, and both companies target decentralized, low-cost sequencing economics — GenapSys primarily at lower throughput than Ultima's UG100/UG200.
- 10x Genomics: Single-cell and spatial biology platform with validated integration onto the UG 100 sequencing platform. 10x is both an Ultima technology partner and a comparable company to the extent that end-customer sequencing decisions may favor 10x-linked workflows on incumbent Illumina versus Ultima.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Ultima Genomics social profiles
Digital presenceUltima Genomics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ultima Genomics leadership team
Management profileNumber of profiles
Profiles18 records
Ultima Genomics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ultima Genomics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ultima Genomics
What does Ultima Genomics do?
Ultima Genomics develops and sells high-throughput DNA sequencing instruments (UG 100, UG200, UG200 Ultra) built on a proprietary open 200mm silicon wafer substrate and flow-based sequencing-by-synthesis chemistry, paired with recurring consumables (wafers, reagents, Solaris/Solaris 2.0 library prep, ppmSeq paired plus-minus chemistry) and on-board analysis software. The company also operates a Technology Access Program providing sequencing-as-a-service and a global Certified Service Provider network for sample-to-data delivery.
Is Ultima Genomics a public or private company?
Ultima Genomics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Ultima Genomics founded?
Ultima Genomics was founded in 2016. It employs 251 to 500 people.
Where is Ultima Genomics based?
Ultima Genomics is headquartered in Newark, United States, in the North America region.
How does Ultima Genomics make money?
Three revenue lines are on record. Instrument hardware sales are the primary driver. The others are consumables (wafers, reagents, adapters, library prep kits) and technology Access Program (sequencing services).
Who are Ultima Genomics's main competitors?
Broad incumbents on record are Illumina and NeoGenomics. Direct peers are Pacific Biosciences, Oxford Nanopore Technologies, MGI Tech (BGI Group), Element Biosciences and Complete Genomics. Emerging players are Singular Genomics, GenapSys and 10x Genomics.
Does Ultima Genomics have an API?
No public API is recorded for Ultima Genomics.
What industry is Ultima Genomics in?
Ultima Genomics's product category is DNA Sequencing Instruments. Its primary akta.pro industry code is HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays). Its NAICS code is 621511 and its SIC code is 3826.